◈ Nootpedia
Compact view
Research pass: medium AAS · Oil injectable SKIP-FOR-NOW MEDIUM-HIGH

Testosterone Enanthate

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict SKIP-FOR-NOW MEDIUM-HIGH

Endogenous testosterone is at lifetime peak in healthy 20yo males; supraphysiologic intervention disrupts a still-developing HPG axis with documented fertility, mood, and lipid risks. Verdict flips to legitimate TRT only if June 2026 panel documents persistent hypogonadism (total T <300 ng/dL on two morning draws + symptoms).

Research pass: medium
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    SKIP

    endogenous T at peak; HPG suppression risk + fertility + mood/lipid hits + zero documented benefit at this age unless pathology present. No cognitive benefit established for eugonadal young men. Verdict re-evaluates after June 2026 panel.

  • 30-50, executive maintenance
    C

    — only with documented low T + symptoms. Enclomiphene preferred first-line for those wanting fertility preservation.

  • 50+, mild cognitive decline
    C

    for symptomatic hypogonadism (T <350 ng/dL + symptoms) — TRAVERSE evidence supports CV safety in this group at TRT doses.

  • Anxiety-prone
    C

    — supra doses can amplify anxiety/irritability; TRT-dose effect variable.

  • High athletic load, tested status
    WADA-

    categorical exclusion for tested athletes. Untested athletes face informed-choice tradeoff (cardiac, fertility, dependence).

  • Sleep-disordered
    C

    — can worsen OSA via Hct + soft tissue.

  • Recovery-focused (post-injury, post-illness)
    S

    low-dose has B-tier evidence in catabolic illness recovery (e.g., HIV wasting, severe burns) but not relevant to gym injuries.

  • Strength/anabolic-focused
    E

    for goal but skip at 20 — endogenous ceiling not yet hit; train + eat + sleep first.

▸ Subjective experience (deep)
  • Onset (TRT 100-200 mg/wk): Subtle. Energy, morning erections, sleep quality improve over 2-6 weeks. Body comp shifts over 3-6 months.
  • Onset (supraphysiologic 400-600 mg/wk): Within 1-2 weeks: noticeable libido + drive surge, training aggression, faster recovery between sessions, water retention, mood lift bordering on hypomania for some.
  • Peak: Plateau by ~week 4-6. Sustained anabolic effect persists for the cycle duration.
  • Taper / post-cycle: Without PCT, crash in ~2-3 weeks post-last-injection. Profound fatigue, libido collapse, depressed mood, fat regain, strength loss for 1-6 months. With PCT (SERM-based): faster recovery but not guaranteed.
  • Characteristic signature: Confidence/aggression dose-dependent; oily skin and acne return of puberty for many; testicular shrinkage within 3-4 weeks at any suppressive dose.
▸ Tolerance + cycling deep dive
  • Tolerance buildup: None to AR effects directly — receptor remains responsive. Tolerance is to the subjective lift (the "feel" plateaus while body comp continues responding).
  • Recommended cycle (if pursued):
    • TRT context: continuous, no cycling, indefinite.
    • Performance context: 10-16 week blast → PCT → minimum 12-16 week off-cycle to recover HPG. "Blast and cruise" (continuous low-dose between blasts) sacrifices natural recovery permanently.
  • Reset protocol if needed (PCT):
    • Stop T, wait for ester clearance (~3-4 weeks for enanthate).
    • SERM stack: clomiphene 50 mg/d × 4 wk → 25 mg/d × 4 wk; or tamoxifen 20 mg/d × 4-6 wk.
    • hCG sometimes added during cycle to maintain testicular volume (250-500 IU 2-3x/week) — does NOT prevent intratesticular suppression long-term.
    • Recovery panel: 4 weeks post-PCT; full natural recovery often takes 3-12 months.
▸ Stacking deep dive

Synergistic with

  • N/A for Dylan — compound is SKIP at this profile. For TRT context only:
  • Anastrozole / aromatase inhibitor: Manages E2 at supraphysiologic doses. Rarely needed at TRT doses.
  • hCG (250-500 IU 2x/wk): Maintains testicular volume + intratesticular T for fertility preservation in younger TRT patients.
  • Finasteride (caveat): Used for hair preservation but blocks 5α-reductase → may attenuate anabolic effect in muscle (controversial) and has its own neuroendocrine side effect profile (post-finasteride syndrome).

Avoid stacking with

  • methyltestosterone: Hepatotoxic 17α-alkylated oral; redundant + dangerous combo.
  • oxandrolone (Anavar): Less hepatotoxic but still 17α-alkylated; HDL crash risk compounds.
  • Other AAS in young men (Tren, Deca, etc.): Each adds specific harms (Tren = neuro/CV/sleep; Deca = prolactin + "deca dick" + much longer suppression).
  • Stimulants at high dose: Compounds CV strain (HR + BP + Hct).

Neutral / safe co-administration

  • Fish oil / EPA (lipid panel mitigation)
  • Telmisartan (BP management if hypertension develops)
  • Standard V4 stack (NAC, magnesium, etc.) — no known interaction
▸ Drug interactions deep dive
  • CYP3A4: Testosterone is a substrate; strong inhibitors (ketoconazole, ritonavir) raise levels modestly.
  • Anticoagulants: T can potentiate warfarin — INR monitoring required.
  • Insulin / oral diabetics: T can improve insulin sensitivity — may require dose adjustment.
  • Corticosteroids: Additive Na/water retention.
▸ Pharmacogenomics
  • AR CAG repeat polymorphism: Shorter CAG repeats (<22) → more sensitive AR → potentially more anabolic + side effect response at given dose. Longer (>24) → less sensitive. Dylan's 23andMe (June 2026) can hint at this via raw data.
  • CYP19A1 (aromatase) variants: Affect E2 conversion rate — some men aromatize aggressively at low doses.
  • SRD5A2 (5α-reductase): Variants affect DHT conversion — relevant to hair and prostate side effect risk.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
US Rx (TRT clinic / telehealth) Marek Health, Defy Medical, Hone, Maximus $100-250/mo all-in High Requires bloodwork showing T <300 ng/dL or below clinic threshold + symptoms; many telehealth clinics have looser thresholds. NOT recommended in absence of pathology.
US Rx (compounding pharmacy via PCP) Empower, Olympia $30-80/mo for vial High Cheapest legitimate route. Requires diagnosis.
US Rx commercial Delatestryl, Xyosted (subQ auto) $200-600/mo via insurance High Brand markup; covered by insurance for diagnosed hypogonadism.
Gray-market UGL "research lab" / overseas $40-80 per 10 mL vial Variable Quality roulette; sterility + dose accuracy not guaranteed; mail interception risk; legal exposure (Schedule III). NOT recommended for Dylan.
▸ Biomarkers to track (deep)
  • Baseline (before any T discussion — Dylan's June 2026 panel):
    • Total testosterone (AM, fasted, 2 separate draws if low)
    • Free testosterone (calculated or measured)
    • SHBG
    • LH, FSH (rules out primary vs secondary hypogonadism)
    • Estradiol (sensitive assay)
    • Prolactin
    • Hematocrit, hemoglobin
    • Lipid panel (HDL, LDL, ApoB, Lp(a))
    • PSA (baseline even at 20 if T discussed)
    • LFTs (AST, ALT, GGT)
    • HbA1c, fasting insulin, glucose
    • Thyroid: TSH, free T4, free T3
  • During use (if ever pursued):
    • 6 weeks post-start: T trough, E2, Hct, lipid
    • 3 months: full panel
    • 6 months: full panel + PSA
    • Annually: full + DRE if indicated
  • Post-cycle (if cycled):
    • 4 weeks post-last-injection: T, LH, FSH, E2
    • 12 weeks post: confirm HPG recovery
    • Sperm analysis if fertility goals
▸ Controversies / open debates Live debate
  • "Bioidentical" framing: True at the molecule level (T is T) but misleading — exogenous T suppresses endogenous regardless. The "natural" branding of TRT marketing oversells safety.
  • TRT at "low normal" T (300-450 ng/dL): Endocrine Society sets threshold at 300 ng/dL; many telehealth clinics treat at 400-500 with symptoms. Genuine controversy — some men have low SHBG and adequate free T despite low total.
  • Cardiovascular risk: Pre-TRAVERSE concern was elevated MACE; TRAVERSE (2023) reassured for hypogonadal CV-risk men at TRT doses. Does NOT clear supraphysiologic doses or healthy young users.
  • Fertility recovery: Some men recover fully post-PCT; others remain subfertile/infertile. Risk factors for non-recovery: longer cycles, higher doses, age >35, baseline low FSH. Younger users at 20 are NOT protected — multiple case reports of permanent oligospermia after a single heavy cycle.
  • Brain development at 20: Limited direct evidence on prefrontal cortex maturation under supraphysiologic T (PFC matures into mid-20s). Animal data + theoretical concern: supraphysiologic androgens may accelerate impulsivity-related neural development. This is a soft concern but worth flagging.
  • Mental health: Aggression literature is contested — meta-analyses show modest increase in irritability/aggression at supra doses, large individual variance.
▸ Verdict change log
  • 2026-05-05 — Initial verdict: SKIP-AT-20 (MEDIUM-HIGH confidence). Rationale: endogenous T at lifetime peak in healthy 20yo, HPG suppression with documented fertility/mood/lipid risks, no demonstrated benefit in eugonadal young men. Re-evaluate post June 2026 bloodwork; only flips to "conditional TRT" with documented hypogonadism (total T <300 ng/dL on two morning draws + symptoms). Even then, enclomiphene preferred first-line for fertility preservation.
▸ Open questions / gaps Open
  • Dylan's June 2026 baseline T, LH, FSH, SHBG — until in hand, this verdict is partially blind.
  • Family history of hypogonadism, fertility issues, or testicular pathology — TBD per profile.
  • AR CAG repeat from 23andMe (raw data analysis post-June 2026) — would inform sensitivity if T ever discussed.
  • Subconcussive impact effect on HPG axis: emerging literature suggests pituitary microtrauma in contact athletes may produce secondary hypogonadism. Worth checking if June panel shows unexpected low T + low LH/FSH pattern in Dylan.
▸ Sources (full, with our context)
  • Bhasin S et al. "The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men." NEJM 1996;335:1-7. — Foundational dose-response for healthy eugonadal men.
  • Lincoff AM et al. "Cardiovascular safety of testosterone-replacement therapy." NEJM 2023;389:107-117 (TRAVERSE). — CV non-inferiority in hypogonadal men.
  • Mulhall JP et al. "Evaluation and management of testosterone deficiency: AUA guideline." J Urol 2018. — Diagnostic + treatment thresholds.
  • Bhasin S et al. "Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline." JCEM 2018;103:1715-1744.
  • Rasmussen JJ et al. "Former abusers of anabolic androgenic steroids exhibit decreased testosterone levels and hypogonadal symptoms years after cessation." PLoS One 2016. — Long-term HPG suppression risk.
  • Coward RM et al. "Anabolic steroid induced hypogonadism in young men." J Urol 2013;190:2200-2205. — Permanent infertility risk in young AAS users.
  • Zitzmann M. "Pharmacogenetics of testosterone replacement therapy." Pharmacogenomics 2009. — AR CAG repeat polymorphism effects.
Back to compact view